Unlock hundreds more features
Save your Quiz to the Dashboard
View and Export Results
Use AI to Create Quizzes and Analyse Results

OR
Sign inSign in with Facebook
Sign inSign in with Google
Quizzes > Quizzes for Business > Healthcare

Test Your Skills: Rheumatoid Arthritis Biologics Knowledge Quiz

Assess Your Understanding of RA Biologic Therapies

Difficulty: Moderate
Questions: 20
Learning OutcomesStudy Material
Colorful paper art illustrating a quiz on Rheumatoid Arthritis Biologics Knowledge

Ready to deepen your understanding of rheumatoid arthritis biologic therapies? This Rheumatoid Arthritis Biologics Knowledge Quiz offers a focused set of MCQs to challenge your grasp of treatment mechanisms, safety profiles, and guideline-based decisions. It's ideal for medical students, healthcare professionals, or anyone aiming to master RA biologics. Feel free to adapt the quiz in our editor to suit your learning style. Explore more quizzes like the Knowledge Assessment Quiz , the Employee Knowledge Quiz , or browse all quizzes for additional practice.

Which of the following agents is classified as a tumor necrosis factor-alpha inhibitor?
Abatacept
Etanercept
Tocilizumab
Rituximab
Etanercept is a TNF-alpha inhibitor that acts as a soluble receptor to bind and neutralize TNF-alpha. Abatacept, tocilizumab, and rituximab target different pathways such as T-cell costimulation, IL-6 receptor, and CD20, respectively.
Which biologic agent directly blocks the interleukin-6 receptor?
Infliximab
Rituximab
Abatacept
Tocilizumab
Tocilizumab is a monoclonal antibody against the IL-6 receptor, blocking IL-6 signaling. Infliximab targets TNF-alpha, rituximab targets CD20, and abatacept blocks T-cell costimulation.
Which agent functions as a CTLA-4 Ig fusion protein to inhibit T-cell costimulation?
Tocilizumab
Etanercept
Abatacept
Adalimumab
Abatacept is a CTLA-4 Ig fusion protein that binds CD80/86 on antigen-presenting cells, preventing T-cell activation. Etanercept and adalimumab inhibit TNF-alpha, while tocilizumab blocks IL-6 receptor.
Which monoclonal antibody depletes B cells by targeting CD20?
Golimumab
Rituximab
Certolizumab
Tocilizumab
Rituximab binds CD20 on B cells leading to depletion through complement and antibody-dependent cytotoxicity. Golimumab and certolizumab are TNF inhibitors, and tocilizumab is an IL-6 receptor antagonist.
What is the primary mechanism of action of infliximab in rheumatoid arthritis?
Blocks interleukin-1 receptor
Binds and neutralizes TNF-alpha
Blocks CD80/86 costimulation
Inhibits JAK enzymes
Infliximab is a chimeric monoclonal antibody that binds and neutralizes TNF-alpha. Blocking IL-1 receptor, inhibiting JAK enzymes, and blocking CD80/86 are mechanisms of other therapies.
After inadequate response to TNF inhibitors, which biologic is often selected next according to guidelines?
Rituximab
Etanercept
Methotrexate
Sulfasalazine
Guidelines recommend switching to a non-TNF biologic such as rituximab after TNF inhibitor failure. Etanercept is also a TNF agent, while sulfasalazine and methotrexate are conventional DMARDs.
Which TNF inhibitor has been most strongly associated with reactivation of latent tuberculosis?
Tocilizumab
Abatacept
Etanercept
Infliximab
Infliximab carries the highest risk of TB reactivation due to potent TNF-alpha blockade. Etanercept has a lower risk, and abatacept and tocilizumab target different immune pathways.
Which of the following is a standard primary endpoint in rheumatoid arthritis biologic clinical trials?
Liver enzyme normalization
ACR20 response rate
Bone mineral density change
DAS44 remission
ACR20 is the standard criterion indicating a 20% improvement in RA symptoms. DAS44 remission is a secondary efficacy measure, while liver enzymes and bone density assess safety and structural changes.
Before initiating a biologic agent, what screening test is recommended to detect latent tuberculosis?
Rheumatoid factor
Serum creatinine
Interferon-gamma release assay
Anti-CCP antibody
An interferon-gamma release assay (or PPD) is recommended to screen for latent TB before starting biologics. Rheumatoid factor and anti-CCP are diagnostic markers, and creatinine assesses renal function.
Which biologic therapy is typically administered as a subcutaneous injection once weekly?
Tocilizumab
Rituximab
Infliximab
Etanercept
Etanercept is given as a subcutaneous injection once weekly. Infliximab and rituximab are administered by intravenous infusion, and tocilizumab can be given IV or monthly subcutaneously.
What is the mechanism of action of tocilizumab in rheumatoid arthritis?
CD80/86 costimulation inhibition
CD20 B-cell depletion
TNF-alpha neutralization
IL-6 receptor blockade
Tocilizumab is a monoclonal antibody that blocks the IL-6 receptor. TNF-alpha neutralizers bind TNF, rituximab depletes B cells via CD20, and abatacept inhibits CD80/86 costimulation.
Infusion-related reactions and hypogammaglobulinemia are most commonly associated with which biologic agent?
Etanercept
Adalimumab
Rituximab
Tocilizumab
Rituximab, an anti-CD20 monoclonal antibody, is known for infusion reactions and can lead to hypogammaglobulinemia. Adalimumab and etanercept have fewer infusion issues, and tocilizumab primarily affects IL-6.
Elevation of liver enzymes is a known laboratory abnormality with which RA biologic?
Tocilizumab
Abatacept
Golimumab
Certolizumab
Tocilizumab can cause elevated transaminases due to IL-6 pathway modulation in the liver. Abatacept and TNF inhibitors like certolizumab and golimumab have lower rates of liver enzyme abnormalities.
In a trial, 50% of patients treated with biologic X achieved ACR20 compared to 30% with placebo. What is the number needed to treat (NNT) to achieve one additional ACR20 responder?
10
2
5
3
The absolute risk reduction is 20% (0.50 âˆ' 0.30), so NNT = 1/0.20 = 5. NNT indicates how many patients need treatment for one to benefit.
Patients with pre-existing demyelinating disease are generally advised to avoid which class of biologic agents?
T-cell costimulation blockers
TNF inhibitors
IL-6 inhibitors
B-cell depleting agents
TNF inhibitors have been associated with the development or exacerbation of demyelinating disease. IL-6 inhibitors, B-cell depleters, and T-cell blockers have not shown the same level of risk.
A 65-year-old RA patient with chronic obstructive pulmonary disease is at higher risk for respiratory infections. Which biologic has the lowest known risk of serious respiratory infections?
Infliximab
Rituximab
Abatacept
Tocilizumab
Abatacept tends to have a lower risk of serious respiratory infections compared to TNF inhibitors and rituximab. Infliximab and rituximab have higher pneumonia risks, and tocilizumab may also impair host defense.
A clinical study reports a hazard ratio of 1.5 (95% CI 1.2 - 1.8) for serious infections with biologic Y versus methotrexate. What does this hazard ratio indicate?
150% lower risk of serious infections
1.5% higher risk of serious infections
50% higher risk of serious infections
No difference in risk
A hazard ratio of 1.5 means there is a 50% increased risk of serious infections with biologic Y compared to methotrexate. A value above 1 indicates an increased hazard.
Which biologic agent is contraindicated in patients with moderate to severe heart failure due to safety concerns?
TNF inhibitors
Tocilizumab
Abatacept
Rituximab
TNF inhibitors, particularly etanercept and infliximab, are contraindicated in moderate to severe heart failure because they can worsen cardiac function. Other biologics do not carry this specific warning.
To maximize vaccine efficacy, when should a patient ideally receive pneumococcal vaccination in relation to starting a biologic agent?
One year after starting therapy
Timing does not affect efficacy
Immediately after the first biologic dose
At least 4 weeks before initiation
Vaccines should be administered at least 4 weeks before starting biologic therapy to ensure an optimal immune response. Vaccinating after initiation may result in reduced immunogenicity.
Meta-analysis data show similar ACR20 response rates for etanercept and adalimumab in RA. What is the primary implication of this finding?
Etanercept is clearly superior
They should not be used interchangeably
Adalimumab has a better safety profile
Both agents have comparable efficacy
Similar ACR20 response rates suggest both etanercept and adalimumab offer comparable efficacy, allowing choice based on patient factors, dosing preferences, or cost. There is no clear superiority between them.
0
{"name":"Which of the following agents is classified as a tumor necrosis factor-alpha inhibitor?", "url":"https://www.quiz-maker.com/QPREVIEW","txt":"Which of the following agents is classified as a tumor necrosis factor-alpha inhibitor?, Which biologic agent directly blocks the interleukin-6 receptor?, Which agent functions as a CTLA-4 Ig fusion protein to inhibit T-cell costimulation?","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}

Learning Outcomes

  1. Identify different classes of biologic agents used in rheumatoid arthritis treatment
  2. Explain mechanisms of action for key RA biologics
  3. Compare efficacy and safety profiles of approved biologic therapies
  4. Apply clinical guidelines to select appropriate biologic treatment
  5. Evaluate patient factors that influence biologic therapy decisions
  6. Interpret clinical trial data on rheumatoid arthritis biologics

Cheat Sheet

  1. Understand the classes of RA biologics - Think of TNF inhibitors as bouncers stopping inflammatory party crashers, while IL-1 and IL-6 blockers calm cytokine storms and B-cell depleters clear rogue antibody producers. Recognizing T-cell co-stimulation blockers completes your superhero lineup for joint protection. Rheumatoid arthritis management
  2. Learn mechanisms of action - Dive into how infliximab blocks tumor necrosis factor-alpha like a dam holding back a flood, anakinra shuts down interleukin-1 alarms, and tocilizumab mutes interleukin-6 broadcasts. Rituximab trims B-cell numbers and abatacept raises the drawbridge on T-cell activation to keep inflammation at bay. Rheumatoid arthritis management
  3. Compare efficacy and safety profiles - See why combining rituximab with methotrexate often steals the show compared to solo acts, yet be mindful that biologics carry a higher infection risk than standard DMARDs. Balancing benefits and safety data is key to a winning treatment plan. Rheumatoid arthritis management
  4. Apply clinical guidelines - Methotrexate usually headlines first for about three months; if the inflammation encore continues, it's time to add a biologic co-star. Following guideline "scripts" ensures evidence-based decisions and better patient outcomes. Rheumatoid arthritis management
  5. Evaluate patient screening factors - Before unleashing TNF inhibitors, always check for hidden tuberculosis stowaways with a skin test or IGRA. Other patient quirks - like liver health and vaccination status - help tailor the safest biologic "costume." Rheumatoid arthritis management
  6. Interpret clinical trial data - Learn to read forest plots and p-values like treasure maps: they reveal which therapies shine under statistical rigour and which might fizzle. Noting head-to-head TNF vs. methotrexate studies can light your study path. Rheumatoid arthritis management
  7. Recognize combination therapy benefits - Teamwork makes the dream work: pairing biologics with methotrexate or leflunomide often outperforms solo missions. Understanding synergy helps you prescribe dynamic duos instead of lone wolves. Rheumatoid arthritis management
  8. Be aware of potential side effects - Every hero has a weakness - biologics can up the risk of infections like TB or fungal invasions. Regular monitoring of blood counts and liver panels keeps you ahead of the villainous side effects. Rheumatoid arthritis management
  9. Understand discontinuation risks - Pulling the TNF inhibitor plug too soon in low-activity patients can spark a flare-up encore. Judicious tapering and shared decision-making help maintain remission without surprise relapses. Rheumatoid arthritis management
  10. Stay informed on emerging therapies - The RA biologics universe is evolving faster than a sci-fi sequel - keep up with new targets, trial results, and biosimilars. Subscribing to journals and conference updates ensures your knowledge stays blockbuster-ready. Rheumatoid arthritis management
Make a Quiz (FREE) Copy & Edit This Quiz Create a Quiz with AI

Healthcare Quizzes

Powered by: Quiz Maker